Phase 2 Irritable Bowel Syndrome Trial, Recruiting NCT06639984 Sponsor: Dr Bruno Chumpitazi, M.D. Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Phase 2 Irritable Bowel Syndrome Trial, Recruiting

NCT06639984
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children who are between 12 and 17 years old and have been diagnosed with Irritable Bowel Syndrome (IBS) based on a specific set of medical guidelines called the Pediatric Rome IV criteria

Who may not be able to join:

  • Children who have had surgery on their bowels, have a diagnosed gut/digestive condition (such as ulcerative colitis), or have a serious ongoing medical condition (such as diabetes)
  • Children whose weight or height is significantly above or below the normal range for their age (confirm with trial site)
  • Children who have a long-term health condition that also affects the digestive system, such as cystic fibrosis
  • Children who have taken antibiotics or probiotic supplements within the last 3 months, as these can affect the natural bacteria in the gut
  • Girls who are pregnant (a urine test will be done at the first visit to check)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bruno Chumpitazi, MD, MPH, Duke University

Phone: 919-660-1227

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dr Bruno Chumpitazi, M.D.
Registry
ClinicalTrials.gov
Start date
20 February 2025
Est. completion
30 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in microbiome composition measured via taxonomic profiling using 16S ribosomal RNA gene amplicon sequencing; Change in fecal lactate; Change in fecal short-chain fatty acids; Change in hydrogen gas production; Change in fecal fructans

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov